FDA OKs First Drug for Nasopharyngeal Carcinoma Toripalimab approved in combination with first-line chemo, and as monotherapy after progression Oct 30, 2023
Wegovy and Thyroid Cancer; Maine Shooter's Mental Health; 469 Heat Deaths Health news and commentary from around the Web gathered by staff Oct 30, 2023
Chinese Compound for MI?; Knee Pain Management Also in TTHealthWatch: a new colorectal cancer screening test Oct 28, 2023 podcast
Soap to Fight Skin Cancer; $1,000 Early Cancer Detection Test; FDA Approval in MDS News, features, and commentary about cancer-related issues Oct 27, 2023
Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease Oct 25, 2023
Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC Time to radiographic progression doubled with 177Lu-PSMA-617 Oct 25, 2023
New Options Challenge Standard Treatments in EGFR-Mutant NSCLC Amivantamab-based regimens improved oncologic outcomes, but with more side effects Oct 25, 2023
Novel Stool RNA Test More Sensitive for Detecting Colon Cancer Versus FIT ColoSense test outperforms fecal immunochemical testing in phase III trial Oct 25, 2023
ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer Adjuvant alectinib reduces disease-free survival hazard by 76% Oct 24, 2023
Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers Still some unanswered questions about benefit over other drug regimens, expert says Oct 24, 2023
Randomized Trial Backs HIF-2a Inhibition in Advanced RCC After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus Oct 24, 2023
More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer PFS doubled and OS improved, driven by mismatch repair-deficient disease Oct 23, 2023
Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy Oct 23, 2023
Targeting KRAS in NSCLC: Recent Progress and New Approaches Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available Oct 23, 2023 video
Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care Oct 23, 2023
Is It a Sports Injury, or Something More Serious? Osteoscarcomas can present to any clinical setting, pediatric researcher says Oct 23, 2023
New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses Oct 23, 2023
'Practice-Changing' Data in Locally Advanced Cervical Cancer Strategies involving immunotherapy, induction chemo move the needle for first time in decades Oct 23, 2023
RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC Two randomized studies demonstrate significantly improved PFS against standard regimens Oct 22, 2023
Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy Oct 22, 2023
Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation Oct 22, 2023
Suzanne Somers' Legacy Tainted by Celebrity Medical Misinformation The actress harnessed the power of traditional media like social media influencers do today Oct 22, 2023
Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer Durvalumab plus olaparib, or alone, paired with chemo boosts PFS in DUO-E trial Oct 21, 2023
Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years And early ctDNA reductions correlated with survival Oct 21, 2023
Carbohydrates and Long-Term Weight Change; Value of Cardiac Transfers Also in TTHealthWatch: reducing infections in joint replacement Oct 21, 2023 podcast
Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer But label update planned after potential harm observed in PD-L1-negative subgroup Oct 20, 2023
Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd Oct 19, 2023
Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment News, features, and commentary about cancer-related issues Oct 19, 2023
Emicizumab Can Delay Immunosuppressive Tx in Acquired Hemophilia A "Strategy will probably be practice-changing," says expert Oct 18, 2023
Senators Grill NIH Director Nominee on Drug Prices, Gender-Affirming Care Monica Bertagnolli, MD, makes her case during confirmation hearing Oct 18, 2023
Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train? It's time for clear guidelines Oct 18, 2023
What Caused the Pigmented Spot on Teen Boy's Eye? Authors discuss how best to diagnose and manage him, given the absence of any symptoms Oct 17, 2023
Pembrolizumab Wins FDA Approval in Operable Lung Cancer Checkpoint inhibitor demonstrated significant survival improvement in perioperative setting Oct 17, 2023
Hemoglobin Targets a Good Idea for Massively Transfused Patients Outcomes improved with values approaching 10 g/dL Oct 16, 2023
Suzanne Somers Dies; FDA Plans to Ban Hair Relaxers; Health Worker Minimum Wage Health news and commentary from around the Web gathered by staff Oct 16, 2023
Study Validates Accuracy of PREDICT Prognostication Tool in Breast Cancer Findings suggest it's a suitable decision aid for U.S. oncologists and patients Oct 13, 2023
Cryoprecipitate, REBOA Flop for Improving Major Hemorrhage Outcomes The first randomized trials of both approaches failed Oct 13, 2023
Hair Relaxers' Cancer Risk; Genetic Test Aids Rural Care; Drug Negotiation Fallout? News, features, and commentary about cancer-related issues Oct 13, 2023
New Lung Cancer Cases Are Higher in Younger Women vs Men And the higher incidence rates now extend to women ages 50 to 54 as well Oct 12, 2023
Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC Encorafenib plus binimetinib led to 75% ORR in untreated patients, 59% in treated patients Oct 12, 2023
